Literature DB >> 31383457

Usefulness of fecal calprotectin as a biomarker of microscopic colitis in a cohort of patients with chronic watery diarrhoea of functional characteristics.

Lissette Batista1, Laura Ruiz1, Carme Ferrer2, Yamile Zabana3, Montserrat Aceituno3, Beatriz Arau1, Xavier Andújar1, Maria Esteve3, Fernando Fernández-Bañares4.   

Abstract

BACKGROUND: Information on the use of fecal markers in microscopic colitis screening is limited. AIM: To evaluate the risk variables associated with a diagnosis of microscopic colitis including fecal calprotectin.
METHODS: Patients submitted for a colonoscopy due to chronic watery diarrhea fulfilling criteria of functional disease were evaluated. Colonic mucosa was normal but mild erythema and edema was allowed. Fecal calprotectin was analyzed. A logistic regression was used to evaluate variables associated with both raised fecal calprotectin and a diagnosis of microscopic colitis.
RESULTS: 94 patients were included, 30 were diagnosed with microscopic colitis and 64 made up the control group. Median calprotectin levels were 175 (IQR, 59-325) for the microscopic colitis and 28 (IQR, 16-111) for the control group (p < 0.001). The optimal cut-off for fecal calprotectin was >100 μg/g (AUC, 0.73), with 67% sensitivity and 75% specificity. The number of drugs used ≥3 (OR, 3.9; CI, 1.4-10.4) and microscopic colitis diagnosis (OR, 6; CI, 2.2-16.3) were associated with raised calprotectin levels. Age >60 years (OR, 3.8; CI, 1.4-10.1) and calprotectin levels (OR, 5.3; CI, 2-14.1) were associated with a risk of microscopic colitis.
CONCLUSIONS: Elevated fecal calprotectin concentrations are often seen in microscopic colitis, and may be helpful in the diagnosis of women over 60 with chronic watery diarrhea.
Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Collagenous colitis; Fecal biomarkers; Lymphocytic colitis

Mesh:

Substances:

Year:  2019        PMID: 31383457     DOI: 10.1016/j.dld.2019.07.002

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

Review 1.  Usefulness of Testing for Fecal Calprotectin in Pediatric Gastroenterology Clinical Practice.

Authors:  Eliza Lężyk-Ciemniak; Magdalena Tworkiewicz; Dominika Wilczyńska; Anna Szaflarska-Popławska; Aneta Krogulska
Journal:  Med Princ Pract       Date:  2020-10-29       Impact factor: 1.927

2.  Faecal Calprotectin and 7-α Cholestenone Levels in Microscopic Colitis: Experience from Edinburgh.

Authors:  Matt Davie; Rebecca Trimble; Alexander R Robertson; Anastasios Koulaouzidis
Journal:  Clin Exp Gastroenterol       Date:  2020-05-04

3.  Mucosal and faecal neutrophil gelatinase-associated lipocalin as potential biomarkers for collagenous colitis.

Authors:  Ingunn Bakke; Gunnar Andreas Walaas; Torunn Bruland; Elin Synnøve Røyset; Atle van Beelen Granlund; Celia Escudero-Hernández; Silje Thorsvik; Andreas Münch; Arne Kristian Sandvik; Ann Elisabet Østvik
Journal:  J Gastroenterol       Date:  2021-08-19       Impact factor: 7.527

4.  Microscopic colitis: Etiopathology, diagnosis, and rational management.

Authors:  Ole Haagen Nielsen; Fernando Fernandez-Banares; Toshiro Sato; Darrell S Pardi
Journal:  Elife       Date:  2022-08-01       Impact factor: 8.713

5.  European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations.

Authors:  Stephan Miehlke; Danila Guagnozzi; Yamile Zabana; Gian E Tontini; Anne-Marie Kanstrup Fiehn; Signe Wildt; Johan Bohr; Ole Bonderup; Gerd Bouma; Mauro D'Amato; Peter J Heiberg Engel; Fernando Fernandez-Banares; Gilles Macaigne; Henrik Hjortswang; Elisabeth Hultgren-Hörnquist; Anastasios Koulaouzidis; Jouzas Kupcinskas; Stefania Landolfi; Giovanni Latella; Alfredo Lucendo; Ivan Lyutakov; Ahmed Madisch; Fernando Magro; Wojciech Marlicz; Emese Mihaly; Lars K Munck; Ann-Elisabeth Ostvik; Árpád V Patai; Plamen Penchev; Karolina Skonieczna-Żydecka; Bas Verhaegh; Andreas Münch
Journal:  United European Gastroenterol J       Date:  2021-02-22       Impact factor: 4.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.